An intervention strategy in the prevention or treatment of a subject having an inflammation-related disease such as Diabetes mellitus, autoimmune disease, inflammatory disease or cardiovascular disease. The intervention strategy preferably relates to administration of a chloro-, fluoro-, or bromo-substituted tryptophan, preferably 6-bromotryptophan, and/or a mono- or di-fatty acid substituted glycerol phosphocholine (GPC), preferably chosen from the group consisting of 1-myristoyl-2-arachidonoyl-glycero-phosphocholine (MA-GPC) and 1-arachidonoyl-glycero-phosphocholine (A-GPC), or any derivative or functional equivalent of these. Alternatively, the intervention relates to administration of a Desulfovibrio species, wherein the Desulfovibrio species is preferably chosen from the group consisting of Desulfovibrio piger, Desulfovibrio fairfieldensis, Desulfovibrio desulfuricans, Desulfovibrio indonensis, Desulfovibrio alaskensis, Desulfovibrio vulgaris, Desulfovibrio vietnamensis and Desulfovibrio gigas.
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (France)
ACADEMISCH MEDISCH CENTRUM (Netherlands)
FEDERAL STATE BUDGETARY INSTITUTION OF SCIENCE INSTITUTE OF CYTOLOGY OF THE RUSSIAN (Russia)
Inventor
Yeremenko, Nataliya
Brouard, Sophie
Tomilin, Alexey
Krasavin, Mikhail
Gureev, Maxim
Abstract
Compounds of formula (I)
Compounds of formula (I)
Compounds of formula (I)
or pharmaceutically acceptable salts and/or solvates thereof. Also, the use of the compounds of formula (I) as immunomodulators and in the treatment of autoimmune diseases, transplanted organ rejection, graft-versus-host-disease and BOB1-related diseases, in which the compounds of formula (I) are administered to subjects in need thereof.
A61K 31/538 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
IMPERIAL COLLEGE INNOVATIONS LIMITED (United Kingdom)
ACADEMISCH MEDISCH CENTRUM (Netherlands)
STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM (Netherlands)
Inventor
Jackson, Heather
Kaforou, Myrsini
Levin, Michael
Zandstra, Judith
Kuijpers, Taco
Isaak De Jonge, Marinus
Abstract
The invention relates to protein signatures, and particularly, although not exclusively, to protein signatures detected in methods and kits for distinguishing between and diagnosing a bacterial and/or viral infection. The invention also relates to the use of a protein signature as a diagnostic or prognostic biomarker for a bacterial and/or viral infection.
The present invention relates to the field of in vitro prognosis of neonatal sepsis. More specifically, the present invention relates to the use of indole-3-aldehyde as a predictive biomarker for the risk of a neonate developing sepsis.
Present disclosure discloses an implantable total artificial heart. The artificial heart includes a first pumping chamber, a second pumping chamber and an actuator disposed between the first pumping chamber and the second pumping chamber. The actuator is configured to operate between a first operating state and a second operating state. Further, the artificial heart includes a plurality of first wires wound around the first pumping chamber and the actuator, and/or a plurality of second wires wound around the second pumping chamber and the actuator. Each of the plurality of first and second wires are configured to compress the first and second pumping chambers relative to operation of the actuator for receiving fluid into and pumping fluid out of the first and second pumping chamber. The configuration of the artificial heart is compact, improves durability and mimicking the natural movement of a human tissue for reducing stress on blood and resulting in fewer side effects.
A61M 60/196 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body replacing the entire heart, e.g. total artificial hearts [TAH]
A61M 60/268 - Positive displacement blood pumps including a displacement member directly acting on the blood the displacement member being flexible, e.g. membranes, diaphragms or bladders
A61M 60/427 - Details relating to driving for positive displacement blood pumps the force acting on the blood contacting member being hydraulic or pneumatic
A61M 60/438 - Details relating to driving for positive displacement blood pumps the force acting on the blood contacting member being mechanical
A61M 60/835 - Constructional details other than related to driving of positive displacement blood pumps
The present invention provides compositions for modulating an immune response in a subject. The compositions include micelles formed from elastin-like peptides (ELPs) that may be bound to immunomodulators. The invention also provides uses of such micelles as adjuvants. Also provided are pharmaceutical formulations including the compositions for use as medicaments, particularly for use in treating cancers, allergy and infectious disease.
The invention relates to a method of estimating a relaxation time (Tl) from gradient echo magnetic resonance images, the method comprising: generating an equation representing a relationship between a relaxation time (Tl) and a Magnetic Resonance Imaging (MRI) signal (5) acquired at an instance after application of one or more RF pulses from a plurality of RF pulses (£) applied after a temporal gap and prior to the acquisition of the MRI signal (5), based on a relaxation factor Ei representing Tl relaxation between two consecutive RF pulses during a repetition time (TR), an additional relaxation factor (El gap) representing additional Tl relaxation caused by the temporal gap, with a duration (Tgap) and a flip angle (a) of the plurality of RF pulses (k), wherein the temporal gap is used for applying preparation pulses that do not influence a longitudinal magnetization of spins in MRI, and wherein the plurality of RF pulses (k) having a pre-defined gap between each other; and estimating the relaxation time (Tl) for a plurality of gradient echo magnetic resonance images acquired based on a relaxation factor, an additional relaxation factor, and a flip angle associated with corresponding gradient echo sequences, based on the equation.
G01R 33/561 - Image enhancement or correction, e.g. subtraction or averaging techniques by reduction of the scanning time, i.e. fast acquiring systems, e.g. using echo-planar pulse sequences
G01R 33/44 - Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
G01R 33/50 - NMR imaging systems based on the determination of relaxation times
G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
B. afzeliiB. afzelii. Advantageously, these antigens allow for unprecedented and unexpectedly high sensitivity and specificity in detection of early Lyme disease.
The invention relates to isolated antisense molecule capable of inhibiting the expression of the LMNA gene in a mammalian cell, wherein said antisense molecule comprises an anti-sense nucleic acid strand which is substantially complementary to a target region of a transcript encoded by the LMNA gene, wherein said antisense nucleic acid strand is at least complementary to SNP rs538089, rs505058 or rs4641 in said target region.
The invention relates to isolated antisense molecule capable of inhibiting the expression of the KCNQ1 gene in a mammalian cell, wherein said antisense molecule comprises an anti-sense nucleic acid strand which is substantially complementary to a target region of a transcript encoded by the KCNQ1 gene, wherein said antisense nucleic acid strand is at least complementary to SNP rs1057128, rs8234 or rs17215465 in said target region.
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (France)
ACADEMISCH MEDISCH CENTRUM (Netherlands)
FEDERAL STATE BUDGETARY INSTITUTION OF SCIENCE INSTITUTE OF CYTOLOGY OF THE RUSSIAN ACADEMY OF SCIENCE (Russia)
Inventor
Yeremenko, Nataliya
Brouard, Sophie
Tomilin, Alexey
Gureev, Maxim
Abstract
The present invention relates to compounds of formula (I) (I) or pharmaceutically acceptable salts and/or solvates thereof. The invention further relates to the use of the compounds of the invention as immunomodulators. The invention further relates to the compounds of the invention for use in the treatment of autoimmune diseases, transplanted organ rejection, graft-versus-host-disease and BOB1-related diseases.
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
12.
ENTOSPLETINIB FOR USE IN THE TREATMENT OF COVID19 PATIENTS
The invention relates to entospletinib (GS-9973) or a pharmaceutically acceptable salt, ester or derivative thereof for use in the treatment of a viral infection.
A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
14.
BCMA AS A TARGET FOR T CELL REDIRECTING ANTIBODIES IN B CELL LYMPHOMAS
Provided are methods for treating non-Hodgkin lymphoma (NHL) in a human subject comprising administering to the subject a therapeutically effective amount of a BCMA- specific antibody. Also disclosed are compositions comprising a BCMA-specific antibody in an amount that is therapeutically effective for treating non-Hodgkin lymphoma (NHL) in a human subject, and a γ-secretase inhibitor
A61P 35/02 - Antineoplastic agents specific for leukemia
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
There is provided a Wnt agonist for use in preventing gastrointestinal tract cancer in a subject, wherein the subject has a genetic predisposition to gastrointestinal tract cancer such as FAP as well as a Wnt agonist for preventing or inhibiting the formation of intestinal pre- cancerous lesions or intestinal adenomas.
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
The invention relates to a kit of parts, consisting of compositions (C1) and (C2) in separate containers, for use in the treatment or prevention of osteoarthritis in a vertebrate, wherein: (a) composition (C1) is a liquid hydrogel formulation comprising a polymer gellant with chemically cross-linkable groups; (b) composition (C2) is an aqueous auxiliary formulation comprising either one or more dissolved cross-linkers Z having two or more reactive groups that can chemically cross-link the polymer gellant by forming covalent bonds; or comprising one or more dissolved compounds Y, selected from the group consisting of oxidant, oxidase, peroxidase and combinations thereof, that initiate or mediate chemical cross-linking of the polymer gellant; wherein said treatment comprises combining compositions (C1) and (C2) to form a liquid hydrogel composition (C3) and administering said liquid hydrogel composition (C3) to the synovial fluid or to the cavity of a synovial joint of the vertebrate, to form a cross-linked hydrogel (C4) in the synovial joint of the vertebrate; or wherein said treatment comprises in a first step administering one of the compositions (C1) or (C2) to the synovial fluid or to the cavity of a synovial joint of the vertebrate and in a second step administering the other of the compositions (C1) or (C2), to form a liquid hydrogel composition (C3) in the synovial joint of the vertebrate that reacts to a cross-linked hydrogel (C4).
The invention relates to a pharmaceutical product comprising therapeutically effective amounts of:
(a) an ALK inhibitor or an antibody-drug conjugate directed to the ALK receptor, and
(b) a TNF-related apoptosis-inducing ligand (TRAIL) receptor agonist.
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
Provided is for a method for determining intra-tumor heterogeneity/ copy number heterogeneity of a tumor of a patient, a computer system for measuring intra-tumor heterogeneity, the computer system programmed to perform (parts of) the method described herein. Also provides is for use of the obtained intra-tumor heterogeneity/ copy number heterogeneity in the diagnosis of a cancer patient, for predicting survival, for stratification of a patients and for following development of a tumor in a patient over time.
Provided is for a method for determining copy number heterogeneity of a sample obtained from a cell culture, a computer system for measuring copy number heterogeneity, the computer system programmed to perform (parts of) the method described herein.
A61M 60/196 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body replacing the entire heart, e.g. total artificial hearts [TAH]
A61M 60/268 - Positive displacement blood pumps including a displacement member directly acting on the blood the displacement member being flexible, e.g. membranes, diaphragms or bladders
A61M 60/427 - Details relating to driving for positive displacement blood pumps the force acting on the blood contacting member being hydraulic or pneumatic
A61M 60/438 - Details relating to driving for positive displacement blood pumps the force acting on the blood contacting member being mechanical
A61M 60/837 - Aspects of flexible displacement members, e.g. shapes or materials
A61M 60/873 - Energy supply devicesConverters therefor specially adapted for wireless or transcutaneous energy transfer [TET], e.g. inductive charging
The present invention relates to the use of allogenic fecal matter for the treatment of cachexia and/or cancer, wherein the allogenic fecal matter is obtained from at least one donor subject, wherein the at least one donor subject has a Body Mass Index (BMI) of at least 30 kg/m2, a HOMA-IR value below 2.5 mg/dL and/or an age below 60 years. Fecal matter from said at least one donor subject may be used to treat cancer and/or related conditions.
NEUTRALIZING ANTIBODIES BINDING TO THE SPIKE PROTEIN OF SARS-COV-2 SUITABLE FOR USE IN THE TREATMENT OF COVID-19, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF
The present invention is related to human antibodies and antigen-binding fragments of human antibodies that bind to the spike protein of the SARS-CoV-2 virus which is the cause of coronavirus disease 2019 (COVID-19), and therapeutic and diagnostic methods of using those antibodies.
A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
A61P 5/48 - Drugs for disorders of the endocrine system of the pancreatic hormones
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 37/00 - Drugs for immunological or allergic disorders
24.
METHOD FOR DETERMINING THE RISK OF A THROMBOEMBOLIC EVENT
The invention relates to a method of determining the bleeding risk of a subject comprising: a. contacting a first sample from the subject with an activation mixture comprising (I) TIX-5, (II) factor Xa or an activation agent for activating directly or indirectly the conversion of factor X to factor Xa, and (III) a phospholipid mixture, b. determining the value of a coagulation function parameter of said sample, c. comparing the coagulation function parameter with a control value, d. determining the bleeding risk based on a comparison between the value of said coagulation function parameter of said first sample and said control value.
The invention relates to a pharmaceutical product comprising therapeutically effective amounts of: (a) an ALK inhibitor or an antibody-drug conjugate directed to the ALK receptor, and (b) a NF-related apoptosis-inducing ligand (TRAIL) receptor agonist.
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
A method of treating or preventing an intracellular bacterial infection, comprising contacting the cell(s) which are infected with an antibacterial agent and a photosensitizing agent and irradiating the cell(s) with light of a wavelength effective to activate the photosensitizing agent, wherein the antibacterial agent is released into the cytosol of the cell(s) and kills, damages or prevents the replication of bacteria in said cell(s) is described. Related uses, and compositions, products and kits for the same are further described.
A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
Embodiments of the present invention provide an ancillary device for the cardiopulmonary bypass and a ventilator. In particular, invention relates to a device comprising a first sensor, a second sensor and a controller configured to receive signals from said sensors, and an output means producing an alarm when the outputs from the first and the second sensors are less than a threshold value for more than a threshold amount of time.
An oncotherapeutic product useful for the treatment of cancer. In a preferred embodiment, the oncotherapeutic product is a combination product or kit comprising, the Programmed Death-1 (PD-1) receptor antagonist agent pembrolizumab and the premature stop codon readthrough agent ataluren useful for the treatment of colorectal cancer.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
29.
FECAL MATTER FOR PREVENTION OR TREATMENT OF AUTOIMMUNE DISEASES
The present invention relates to the use of fecal matter in the treatment of a subject having autoimmune disease, wherein the fecal matter is autologous to the subject, and preferably administered to the small intestine, preferably the duodenum, of the subject. The fecal matter can be one or more constituents of autologous feces, preferably chosen from the group consisting of bacteria, viruses, bacteriophages, fungi, metabolites, microRNAs, proteins, antibodies, and/or antigens.
A high-performance single-chip, integrated-optics-based OCT system is disclosed, where the length of the reference arm is digitally variable. The reference arm includes a plurality of switch stages comprising a 2×2 tunable wavelength-independent waveguide switch that can direct an input light signal onto either of two different-length output waveguides. In some embodiments, the directional couplers are thermo-optic based. Some embodiments include a solid-state scanning system for scanning a sample signal along a line of object points on the sample under test.
The present invention provides a method of treating or preventing an intracellular bacterial infection, comprising contacting the cell(s) which are infected with an antibacterial agent and a photosensitizing agent and irradiating the cell(s) with light of a wavelength effective to activate the photosensitizing agent, wherein the antibacterial agent is released into the cytosol of the cell(s) and kills, damages or prevents the replication of bacteria in said cell(s). The invention also provides related uses, and compositions, products and kits for the same.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
The invention relates to an isolated, recombinant or synthetic polypeptide comprising an Env polypeptide of an HIV virus, the Env polypeptide comprising at least the amino acid residues K275, D276 and R278, wherein said numbering is according to the HxB2 reference sequence having the amino acid sequence of SEQ ID NO: 1.
A low coherence interferometry imaging system comprising a common-path interferometer that is at least partially integrated as part of a planar lightwave circuit is disclosed. Imaging systems in accordance with the present invention are implemented in integrated optics without the inclusion of highly wavelength-sensitive components. As a result, they exhibit less wavelength dependence than PLC-based interferometers of the prior art. Further, the common-path interferometer arrangement of the present invention avoids polarization and wavelength dispersion effects that plague prior-art PLC-based interferometers. Still further, an integrated common-path interferometer is smaller and less complex than other integrated interferometers, which makes it possible to integrate multiple interferometers on a single chip, thereby enabling multi-signal systems, such as plane-wave parallel OCT systems.
The invention relates to a kit of parts comprising an inhibitor of BMP2 and an inhibitor of BMP4 or an inhibitor of BMP2 and BMP4 for use in the treatment of Barrett's Esophagus or for the prevention of esophageal adenocarcinoma. The invention further relates to pharmaceutical composition comprising a kit of parts comprising an inhibitor of BMP2 and an inhibitor of BMP4 or an inhibitor of BMP2 and BMP4 as defined herein and a pharmaceutically acceptable carrier or diluent for use in the treatment of Barrett's Esophagus or for the prevention of esophageal adenocarcinoma.
The invention relates to a method of diagnosing or screening for 27 -hydroxylase (CYP27A1) deficiency in an animal comprising: determining in a biological sample the intensity signal by mass analysis of at least a bile alcohol glucuronide and a C24- or C27-bile acid or a conjugate thereof, comparing the intensity signals to a control sample or control value, and determining 27-hydroxylase (CYP27A1) deficiency based on said comparison.
The invention relates to a method for determining the survival prognosis of a patient admitted to an intensive care unit (ICU) or a sepsis patient, comprising steps of determining the expression level of at least BPGM and/or TAP2 in a biological sample of said patient, and compare said expression level(s) with a control and, determine said survival prognosis based on said comparison.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
37.
BIOMARKERS FOR DETERMINING THE PRESENCE OF AN UNSTABLE ATHEROSCLEROTIC PLAQUE
The invention relates to a method for determining the presence of an unstable atherosclerotic plaque in an individual, comprising the steps of determining the expression level of one or more miRNA(s) selected from the group consisting of miR-223-3p, miR-125b-5p, miR-142-3p and miR-193b-3p in a biological sample from said individual; comparing said expression level(s) with a reference level, and determining presence of said unstable atherosclerotic plaque based on said information. The same miRNA species and miR-499a-5p may be used in the diagnosis of risk of suffering from or developing atherosclerosis.
The invention provides a method of determining the risk of developing rheumatoid arthritis in a subject comprising the steps of determining in a biological sample from said subject the number and/or frequency of dominant BCR clones, and determining the risk of developing rheumatoid arthritis based on said number of dominant BCR clones, wherein an increase of said number of dominant BCR clones and/or a higher frequency of at least one dominant BCR clone compared to a healthy control indicates an increased risk. In a preferred embodiment, said increased risk is indicated when at least 0.5% of the total number of BCR clones is a dominant BCR clone.
The present invention relates to genetically modified HepaRG cells as deposited on 10-5-2016 at the Leibniz-lnstitut DSMZ Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, under No. DSM ACC3291. The invention further relates to methods of culturing said cells and cell cultures comprising said cells. The invention further relates to uses of the genetically modified HepaRG cells.
The present application relates to an assembly for a joint (1, 2, 3, 4), the joint comprising a joint implant (5, 6) between a proximal segment of a limb that is proximal to the joint and a distal segment of the limb that is distal to the joint and in which the joint is configured to allow rotation of the proximal and distal segments with respect to one another about an axis that intersects a first plane, and to inhibit rotation in the second and third plane, both perpendicular to the first plane, the assembly being for subjecting the joint at predetermined angles of the joint rotation in the second and third plane to a defined bending moment to induce a load to the implant that causes a movement of the implant in relation to the bone of the proximal or distal segments.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
41.
BIOMARKER FOR RISK STRATIFICATION IN CARDIOVASCULAR DISEASE
The invention relates to a miRNA that is useful in the risk stratification of heart failure patients, and especially in the risk stratification of heart failure patients The invention further relates to the use of this miRNA and methods wherein this miRNA is used in expression profiling for risk stratification. The expression of the miRNA of the invention provide information on the risk of re-hospitalization and mortality following the period (generally one year) after the initial sampling (obtaining the biological sample from the patient). The risk stratification provides information about the risk of worsening of the disease and the complications that might come with it.
The invention relates to a flow cytometry method for determination of size and/or refractive index of substantially spherical single particles, wherein the method comprises the following steps: calibrating a flow cytometer based on light scattering signals, performing a flow cytometry experiment, wherein the flow cytometer experiment comprises illuminating a flow cell of the flow cytometer by an illumination beam and subsequently detecting a first and a second light scattering signal of the single particles in the flow cell, wherein the first and second light scattering signal are differentiated by a polarization state relative to the illumination beam, a wavelength of the illumination beam, and/or a scattering angle, and analyzing data resulting from the flow cytometry experiment for determination of size and/or refractive index of the single particles. The invention also relates to a flow cytometer calibration method.
The invention relates to a method for determining the risk of suffering from or developing a coronary artery disease (CAD), atherosclerosis or a cardiovascular disease of a smoker, comprising: determining in a biological sample from the smoker the expression level of mi R-124-3p, comparing said expression level with a reference level, and determining said risk based on said comparison.
A non-destructive method of estimating hematocrit (Hct) of whole blood from a dried blood sample prepared from the whole blood, the method comprising: a) determining the amount of hemoglobin derivatives comprising oxyhemoglobin, met-hemoglobin and hemichrome (total hemoglobin) in a dried blood sample, wherein the sum of the amounts of the hemoglobin derivatives remains constant in the dried blood sample in function of time, and b) estimating the hematocrit from the sum of the amounts of the hemoglobin derivatives, wherein the hematocrit is estimated using a calibration curve providing a correlation between hematocrit and the amount of the hemoglobin derivatives in a dried blood sample. The amount of the hemoglobin derivatives is preferably determined by measuring the reflectance, absorbance, or transmittance of the dried blood sample at the quasi-isosbestic point of the hemoglobin derivatives about 589 nm or at multiple wavelengths within the range of 450 to 750 nm.
G01N 21/31 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
The invention relates to an isolated, recombinant or synthetic polypeptide comprising an Env polypeptide of an HIV virus comprising a gp120 polypeptide portion and at least a gp41 ectodomain polypeptide portion from HIV-1 or a gp125 polypeptide portion and at least a gp36 ectodomain polypeptide portion from HIV-2, wherein said gp120 or gp125 polypeptide portion and said gp41 or gp36 ectodomain polypeptide portion comprise a first cysteine residue at an amino acid position equivalent to amino acid position 49, 50, 51, 71, 72 or 73 and a second cysteine residue at an amino acid position equivalent to amino acid position of a residue selected from the group consisting of: 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569 and 570, wherein numbering is according to the HxB2 reference sequence having the amino acid sequence of SEQ ID NO: 1, and wherein said first and said second cysteine residues form an intermolecular disulfide bond. The invention further relates to an isolated, recombinant or synthetic polypeptide comprising an Env polypeptide of an HIV virus comprising a gp120 polypeptide portion and at least a gp41 ectodomain polypeptide portion from HIV-1 or a gp 125 polypeptide portion and at least a gp36 ectodomain polypeptide portion from HIV-2, wherein said Env polypeptide comprises at least one amino acid residue selected from the group consisting of: 64K and 66R; and 302F, 302W, 304F, 304W, 306L, 307F, 307W, 308L, 315Y, 315K, 3151, 315W, 315F, 315V, 316Y, 316K, 3161, 316F, 316W, and 316V; and 555K or 556K; and 137A, wherein numbering of said at least one amino acid residue is according to the HxB2 reference sequence having the amino acid sequence of SEQ ID NO: 1, and wherein said at least one amino acid residue is at an amino acid position equivalent to the amino acid position of SEQ ID NO: 1.
A low coherence interferometry Imaging system comprising a common-path Interferometer that is at least partially integrated as part of a planar lightwave circuit Is disclosed. Imaging systems in accordance with the present invention are Implemented in Integrated optics without the inclusion of highly wavelength-sensitive components, As a result, they exhibit less wavelength dependence than PLC-based Interferometers of the prior art. Further, the common-path interferometer arrangement of the present invention avoids polarization and wavelength dispersion effects that plague prior-art PLC-based interferometers. Still further, an integrated common-path Interferometer is smaller and less complex than other integrated interferometers, which makes It possible to Integrate multiple interferometers on a single chip, thereby enabling multi-signal systems, such as plane-wave parallel OCT systems.
The invention relates to a method for diagnosing whether a patient is at risk of suffering from community acquired pneumonia (CAP) comprising steps of: (a) determining the expression levels of FAIM3 and PLAC8 in a biological sample of said patient; (b) comparing said expression levels with a reference control, and (c) determining the risk of suffering from CAP based on said expression levels. In a preferred embodiment, said step (a) comprises determining the ratio of the expression levels of FAIM3 and PLAC8, and step (b) comprises determining said risk based on said ratio.
The invention provides a flushing system (1) configured to flush the pericardial cavity (PC) of a patient, wherein the system comprises: an infusion liquid outlet (4) to connect a first tube(20) having an infusion liquid lumen to guide a flow of infusion liquid from the system to the pericardial cavity, and an effusion liquid inlet (6) to connect to a second tube (21) having an effusion liquid lumen to guide the effusion liquid flow from the pericardial cavity to the system, a flow rate control system to control the flow rate of the infusion liquid flow at the infusion liquid outlet (4) on the basis of multiple sensor signals, wherein the flow rate control system comprises: a control unit (5) to provide a control signal on the basis of the sensor signals, and a pump device (3) to pump infusion liquid to the infusion liquid outlet (4) at an infusion liquid flow rate, wherein the infusion liquid flow rate is adjustable by the control signal of the control unit (5) and wherein the sensor signals registered by the control unit (5) comprise: an infusion liquid signal representative for the infusion liquid flow to the pericardial cavity, an effusion liquid signal representative for the effusion liquid flow rate from the pericardial cavity, a blood volume signal generated by a hematocrit sensor (12) representative for a blood loss flow rate in the effusion liquid from the pericardial cavity, and a pressure control signal representative for the pressure in the pericardial cavity generated by a pressure sensor positioned inside or in connection with the first tube (20), the second tube (21) or the pericardial cavity. The invention also provides a method of monitoring the blood loss volume or flow rate from the pericardium based on multiple sensor signals as well as, a method of treatment of postoperative cardiac patients in order to reduce the risk of cardiac tamponade, reduce post-operative blood loss and reduce the accumulation of blood and clots in the pericardial cavity, wherein the pericardial cavity of the patient is flushed with a flushing system according to the invention.
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
The invention relates to methods for quantification of the amount of target mi RNA in biological samples using normalization. In particular, the invention relates to methods for quantifying mi RNAs in serum, whole bold or platelets samples. The invention further relates to kits for quantifying the amount of a target mi RNA in a biological sample.
The invention provides a method for determining whether a patient is sensitive or insensitive to a treatment with a thromboxane A2 inhibitor or a selective COX-1 inhibitor for use in a platelet inhibition treatment comprising the steps of: a. determining the expression level of one or more mi RNA(s) selected from the group consisting of miR-19b-1-5p, miR-1271, and miR-1537-5p, in a sample comprising platelet derived nucleic acids, b. comparing said expression level with a reference level, and c. determining the sensitivity or insensitivity of said subject for a treatment with said thromboxane A2 inhibitor or said selective COX-1 inhibitor based on the information obtained in step b.
The invention relates to antimicrobial peptides, pharmaceutical compositions comprising the peptides and to uses thereof for in the treatment or prevention of microbial, bacterial, fungal, viral and parasitic infection.
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A01N 43/38 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings condensed with carbocyclic rings
The invention provides devices, apparatuses, systems and methods for treating and ameliorating inflammation of the gut. In particular, the invention provides devices, apparatuses and methods in which a neuromodulatory signal is delivered a splenic nerve and/or superior mesenteric plexus (SMP). The signal is able to treat inflammatory disorders, e.g., colitis, for example in Inflammatory Bowel Disease.
A compound selected from the group consisting of: (i) an inhibitor of Polo-like 1 (PLK1), (ii) an inhibitor of mammalian Ste20-like 1 (MST1), and (iii) an inhibitor of RAF-1, with the proviso that said compound is not an M-CSF antagonist, for use in a treatment of a subject infected with a retrovirus or for prevention of infection with a retrovirus in a subject, preferably wherein said treatment is given before seroconversion.
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
The invention relates to an NK3 agonist or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of an atrial arrhythmia. The invention further relates to a composition comprising an NK3 agonist for use in the treatment of a patient suffering from a disease wherein the electrical activity of an atrial heart cell is affected.
The invention therefore provides a compound effective against Ralstonia pickettii for use in the treatment or prevention of insulin resistance, obesity or type II diabetes of a subject. Preferably, said compound is selected from the group consisting of an antibiotic effective against Ralstonia pickettii, an immunogenic compound capable of producing a protective immune response in a subject, and an antibody which specifically binds to Ralstonia pickettii or a binding fragment thereof. The invention further provides an in vitro method of diagnosis or prediction of insulin resistance, obesity or type II diabetes in a subject, comprising determining the presence of Ralstonia pickettii or the presence of an antibody which specifically binds to Ralstonia pickettii in a test sample of said subject. In another aspect, the invention provides the use of an antibody binding specifically to an antigen of Ralstonia pickettii, a Ralstonia pickettii cell, and/or a nucleic acid hybridizing under stringent conditions to a nucleic acid from Ralstonia pickettii in a method according to the invention. The invention further provides the use of a kit comprising said antibody, a nucleic acid as defined in above, and optionally comprising a Ralstonia pickettii bacteria or a nucleic acid or protein thereof, a further reagent or a conventional kit component.
Deoxynojirimycin and deoxygalactonojirimycin derivatives according to the present invention are N-alkylated D-galacto, D-gluco- or L-ido- deoxynojirimycin with a linear methyloxypentyl group bearing various sidegroups and a non-fused bicyclic aromatic group ("X") on the methyloxy- carbon. Formula (I), Formula (Ia). These compounds display an increased inhibitory potency towards GCS, and/or an increased inhibitory potency towards GBA2, and/or a decreased inhibitory potency towards GBA1, relative to known deoxynojirimycin derivatives of the same (D-gluco, L-ido or D-galacto) configuration. Therefore, compounds of the present invention are effective in the treatment of diseases which are associated with an irregular level of cytosolic or lysosomal glucosylceramide and/or higher glycosphingolipids, such as a lysosomal storage disorder, such as Gaucher disease, Fabry disease, Tay- Sachs disease, Sandhoff disease, GM1 gangliosidosis, Sialidosis, Niemann Pick disease type C and AMRF, or a symptom of one of the diseases collectively classed as metabolic syndrome, such as obesity, insulin resistance, hyperlipidemia, hypercholesterolemia, polycystic kidney disease, type II diabetes and chronic inflammation, or a neurodenegerative disorder, such as Parkinson disease or Lewy-body dementia.
C07D 211/46 - Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
The invention provides a recombinant collagen or gelatin micro-carrier crosslinked by hexamethylenediisocyanate (HMDIC) comprising stromal cells for use in the treatment of cardiovascular disease. The invention is also directed at applications in which such cell carriers loaded with adipose derived stromal cells are used, for example as injectable cell carrier, for treatment of cardiovascular disease or treatment of damage of other tissues and organs.
The invention relates to thrombocidin-derived antimicrobial peptides, pharmaceutical compositions comprising the peptides and to uses thereof for in the treatment or prevention of microbial, bacterial, fungal, viral and parasitic infection.
The invention provides a flushing system (1) configured to flush the pericardial cavity (PC) of a patient, wherein the system comprises: an infusion liquid outlet (4) to connect a first tube(20) having an infusion liquid lumen to guide a flow of infusion liquid from the system to the pericardial cavity, and an effusion liquid inlet (6) to connect to a second tube (21) having an effusion liquid lumen to guide the effusion liquid flow from the pericardial cavity to the system, a flow rate control system to control the flow rate of the infusion liquid flow at the infusion liquid outlet (4) on the basis of multiple sensor signals, wherein the flow rate control system comprises: a control unit (5) to provide a control signal on the basis of the sensor signals, and a pump device (3) to pump infusion liquid to the infusion liquid outlet (4) at an infusion liquid flow rate, wherein the infusion liquid flow rate is adjustable by the control signal of the control unit (5) and wherein the sensor signals registered by the control unit (5) comprise: an infusion liquid signal representative for the infusion liquid flow to the pericardial cavity, an effusion liquid signal representative for the effusion liquid flow rate from the pericardial cavity, a blood volume signal generated by a hematocrit sensor (12) representative for a blood loss flow rate in the effusion liquid from the pericardial cavity, and a pressure control signal representative for the pressure in the pericardial cavity generated by a pressure sensor positioned inside or in connection with the first tube (20), the second tube (21) or the pericardial cavity. The invention also provides a method of monitoring the blood loss volume or flow rate from the pericardium based on multiple sensor signals as well as. a method of treatment of postoperative cardiac patients in order to reduce the risk of cardiac tamponade, reduce post-operative blood loss and reduce the accumulation of blood and clots in the pericardial cavity, wherein the pericardial cavity of the patient is flushed with a flushing system according to the invention.
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
The invention relates to antimicrobial peptides, pharmaceutical compositions comprising the peptides and to uses thereof for in the treatment or prevention of microbial, bacterial, fungal, viral and parasitic infection.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
The invention therefore provides a method for detecting an uncommitted Leydig progenitor cell in a sample of testis cells comprising detecting the presence of CD 146 on the membrane of said cell. The invention further provides a method for selecting an uncommitted Leydig progenitor cell in a sample of testis cells comprising detecting uncommitted Leydig progenitor cell using the above mentioned method of detection and selecting said uncommitted Leydig progenitor cell.
An arthroscopic instrument assembly (100), comprising: an illumination system (120) for illuminating an operative field, including a light source (122a) configured to produce light having at least one ligament excitation wavelength; an arthroscope (110); an image transmission system (130) configured to transmit a fluorescent image of the operative field at a distal end (112b) of the arthroscope (110) to an image viewing system (150); an image processing system (140) configured to process the fluorescent image as it passes through the image transmission system, so as to provide a false-color fluorescent image of the operative field in which a contrast between ligament and bone structures present in the operative field is enhanced relative to the unprocessed fluorescent image; and an image viewing system (150), operably connected to the image transmission system (130), and including a display (152) configured to enable viewing of the false-color fluorescent image.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 1/317 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for introducing through surgical openings, e.g. laparoscopes for bones or joints, e.g. osteoscopes, arthroscopes
66.
MEANS AND METHODS FOR RESPONSE PREDICTION OF HEPATITIS B TREATMENT
The present invention provides means and methods for determining whether a hepatitis B patient is susceptible to hepatitis B treatment, comprising determining whether a sample of the patient comprises nucleic acid with nucleotide polymorphisms that are associated with a positive outcome of hepatitis B treatment and/or determining whether a sample of the patient comprises an expression level of carnitine or of a carnitine derivative that is associated with a positive outcome of hepatitis B treatment. Compositions, kits of parts, (micro)arrays and vectors useful for such methods are also herewith provided.
The present invention relates in general to prevention, reduction or treatment of rejection in transplant patients. In particular the invention relates to the use of SSRIs (selective serotonin reuptake inhibitors) for the prevention, reduction or treatment of rejection in transplant patients, such as blood cell, stem cell, bone marrow, tissue or organ rejection.
A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
The present invention provides a method of determining the risk of developing metastasis and/or tumor relapse in a colorectal cancer patient, comprising the steps of providing a biological sample of said colorectal cancer patient, and determining in said biological sample the methylation status and/or the expression level of a gene selected from the group consisting of LGR5, APCDD1, ΑΧIΝ2, DKK1, and ASCL2, and determining an increased risk of developing metastasis and/or tumor relapse, under the condition that hypermethylation and/or under expression is determined in a gene selected from the group consisting of LGR5, APCDD1, ΑΧΓΝ2, DKK1, and ASCL2.
A method of prognosticating progression of Barrett's esophagus in a patient comprising detecting in a sample of esophageal cells from the patient at least one abnormality selected from the group consisting of pi 6 loss, p53 loss, chromosome 7 aneuploidy, and chromosome 17 aneuploidy, which method can further comprise detecting at least one abnormality selected from the group consisting of 20q gain, C-myc gain, and Her2 gain; and a kit comprising (a) a set of probes comprising a probe for pi 6, a probe for p53, a probe for chromosome 7, and a probe for chromosome 17 and (b) instructions comprising determining at least one abnormality selected from the group consisting of p16 loss, p53 loss, chromosome 7 aneuploidy, and chromosome 17 aneuploidy, which kit can further comprise at least one additional probe selected from the group consisting of a probe for 20q, a probe for C-myc, and a probe for Her2 and additional instructions comprising determining at least one additional abnormality selected from the group consisting of 20q gain, C-myc gain, and Her2 gain.
The present invention describes use of Eubacterium hallii et rel. and/or Alcaligenes faecalis et rel., as well as pharmaceutical, food, or feed compositions comprising these bacteria, as a medicament, in particular for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as metabolic syndrome, dyslipidemia and type 2 diabetes mellitus as well as insulin resistance in endocrine diseases (e.g.,obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes. Also described is a method for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as dyslipidemia and type 2 diabetes mellitusas well as insulin resistance in endocrine diseases (e.g.,obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes)in a subject in need thereof, said method comprising the step of increasing the level of Eubacterium hallii et rel. and/or Alcaligenes faecalis et rel. in the small intestine.
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (Switzerland)
ACADEMISCH MEDISCH CENTRUM (Netherlands)
Inventor
Auwerx, Johan
Houtkooper, Richardus
Houten, Sander
Argmann, Carmen
Abstract
The present invention relates to novel biomarkers for aging and healthspan, methods and uses thereof, in particular, for determining the biological age of a subject and/or preventing or delaying aging process in a subject, and kits for use in said methods.
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
ACADEMISCH MEDISCH CENTRUM (Netherlands)
Inventor
Ackerman, Michael J.
Giudicessi, John R.
Pinto, Yigal Martin
Amin, Ahmad Shoaib
Tijsen, Anke Johanna Marina
Wilde, Arthur, Arnold, Maria
Abstract
This document provides methods and materials involved in assessing and treating humans with LQTS or with a potential mutation in a KCNQ1 nucleic acid that encodes a Kv7.1 potassium channel subunit. For example, methods and materials for determining if a human containing a mutation in a KCNQ1 nucleic acid that encodes a Kv7.1 potassium channel subunit on one allele also contains, on the same allele (a cis relationship) or on the other allele (a trans relationship), a genetic variation (e.g., a SNP) in a 3' UTR of KCNQ1 nucleic acid that creates a miR-378 binding site are provided.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 25/00 - Drugs for disorders of the nervous system
73.
APPARATUS AND METHOD FOR DATING A BODY OR BODY SAMPLE
A method and apparatus for dating a dating a body sample, such as blood, includes taking at least one spectroscopic measurement (37) of the sample at least two predetermined positions in the spectrum having spectral characteristics corresponding to at least two predetermined substances present in the sample that have a time varying relationship with each other. A measured relative concentration of each of the predetermined substances is then determined (41) from the measurement, and the measured relative concentrations of the two predetermined substances is compared (43) with a known variation of the relative concentrations of the two predetermined substances over time. A good fit of the measured relative concentrations to the known variation of the relative concentrations is then determined, so as to provide an indication of the age of the sample (44). Alternatively, instead of measuring the relative concentrations of each of the predetermined substances, the rate of change of the relative concentrations is determined.
G01N 21/27 - ColourSpectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection
G01N 21/31 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
74.
METHODS FOR ASSESSING THE SUSCEPTIBILITY OF A HUMAN INDIVIDUAL FOR NARROWING OF BLOOD VESSELS AFTER VASCULAR INTERVENTION
The present invention relates to methods for assessing the susceptibility of a human individual for narrowing of blood vessels after vascular intervention, and especially in-stent restenosis. Especially, the present inventions relates to method for assessing the susceptibility of a human individual for narrowing of blood vessels, after vascular intervention, comprising:1) determining, in a sample originating from said human individual, the genotype of the cyclin-dependent kinase inhibitor p27kip1 encoding gene and/or nuclear receptor Nurr1 encoding gene; and 2) establishing the susceptibility of a human individual for narrowing of blood vessels after vascular intervention based on said determination.
The present invention provides means and methods for counteracting and/or preventing aggregation of a polyQ protein. Further provided are improved poly constructs which are, amongst other things, useful for testing assays. According to the invention, several peptidases like, e.g. tripeptidyl peptidase II (TPPII), appear to be capable of cleaving long polyQ peptides comprising at least 45 glutamine residues. Hence, according to the invention, administration of such peptidases to an individual suffering from a polyQ expansion disorder results in degradation of long polyQ peptides.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
C12N 15/62 - DNA sequences coding for fusion proteins
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
76.
METHODS FOR ASSESSING THE SUSCEPTIBILITY OF A HUMAN INDIVIDUAL FOR NARROWING OF BLOOD VESSELS AFTER VASCULAR INTERVENTION
The present invention relates to methods for assessing the susceptibility of a human individual for narrowing of blood vessels after vascular intervention, and especially in-stent restenosis. Especially, the present inventions relates to method for assessing the susceptibility of a human individual for narrowing of blood vessels, after vascular intervention, comprising: 1) determining, in a sample originating from said human individual, the genotype of the cyclin-dependent kinase inhibitor p27kip1 encoding gene and/or nuclear receptor Nurr1 encoding gene; and 2) establishing the susceptibility of a human individual for narrowing of blood vessels after vascular intervention based on said determination.
The present invention relates to a binding compound which binds to human APRIL. More specifically the invention provides, compositions of anti-APRIL specific antibodies and methods to use such antibodies in modulating the biological activity APRIL, particularly in inflammatory diseases, inhibition of cell proliferation and cancer.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
78.
DRUG DELIVERY SYSTEM FOR USE IN THE TREATMENT OF VASCULAR AND VESSEL-RELATED PATHOLOGIES
The present invention relates to a drug delivery system for use in the treatment of vascular and vessel-related pathologies, comprising a drug delivery platform that comprises at least one compound capable of exerting an effect on the formation and/or maintenance of a thrombus in the vessel to be treated. The platform is preferably formed by liposomes that are sterically stabilized by grafting of poly(ethylene glycol) onto the liposome surface. The liposomes may further comprise photosensitizers and targeting molecules. The liposomes may be thermosensitive. The compound is suitably tranexamic acid. The drug delivery system is preferably used for the treatment of port wine stains.
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
A method and apparatus for dating a body sample, for example a sample of body fluid involves taking a series of spectroscopic measurements of the sample, each measurement in the series including at least two predetermined positions in the spectrum. The positions have spectral characteristics corresponding to two or more predetermined substances present in the sample that have a time varying relationship with each other. The measurements in the series are spaced in time. A concentration of each of the substances present in the sample is then determined from each of the spectroscopic measurements at each point in time. Next, a ratio of the concentrations of the two predetermined substances at each point in time is determined and then the ratios of the concentrations of the two predetermined substances over time are analysed to estimate when the concentrations of the two substances were at a limit of their concentrations, thereby providing an indication of the age of the sample. The sample may be blood, which may be either within the body (e.g. as a bruise), or external to the body.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/103 - Measuring devices for testing the shape, pattern, size or movement of the body or parts thereof, for diagnostic purposes
G01N 21/31 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
G01N 33/487 - Physical analysis of biological material of liquid biological material
G01N 33/49 - Physical analysis of biological material of liquid biological material blood
LEIDEN UNIVERSITY RESEARCH & INNOVATION SERVICES (LURIS) (Netherlands)
Inventor
Aerts, Johannes Maria Franciscus Gerardus
Overkleeft, Herman Steven
Abstract
The present invention relates to compounds according to formula (I) : wherein R2 is absent or a linking moiety and R3 is selected from the group consisting of anti- inflammatory agents and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising compounds of formula (I) and the use of these pharmaceutical compositions for the treatment or prophylaxis of chronic inflammatory diseases, in particular those that are caused by chronically activated macrophages. The chronic inflammatory disease is in particular atherosclerosis, (rheumatoid) arthritis, an (auto) immune disease.or sarcoidosis.
The current invention provides a process for determining the TCR or BCR receptor gene rearrangements and allows visualization of the repertoire of V(D)J rearranged CDR3 domains on an oligonucleotide array on a solid carrier. The method visualizes the end-result of the V(D)J recombination process and in particular the delet ion and insertion process that takes place in the NDN hypervariable region, where 1 up to 13 nucleotides are deleted from the V, D and/or J gene segments, by using a labeled annealer oligonucleotide that hybridizes on or in close proximity of the NDN region. The method allows detection of the full repertoire or a selected part of the repertoire, by choosing and combining primers that are specific for certain V, D and/or J gene segments flanking the CDR3 on either side. The method of the invention may be used or applied for the diagnosis of an immune response against a pathogen, allergen or auto-allergen.
The present invention discloses a therapeutic target for the treatment of cyst ic fibrosis. It was found that inhibition of non-lysosomal glucosylceramidase (GBA2) sufficiently restores chloride current in cells from CF patients carrying the common delF508-CFTR mutation. With the catalytic centre (4) of the enzyme positioned on top of the membrane bilayer face particularly potent inhibitors are found in deoxynojirimycin derivatives having a group that is capable of inserting in the membrane bilayer.
patents
